| Literature DB >> 35222639 |
Keyvan M Safdari1,2, Curtis Converse1, Fanglong Dong1,3, Nickolas Alan MacDougall1, Kevin Hyer1,4, Alec Runyon1,4, Haley Ahlering1, Mark E Comunale1.
Abstract
DESIGN: A retrospective analysis of all anesthetic records at our institution over a two-year period was performed. Setting. Operating room cases under balanced anesthesia. Patients. All patients with ASA class I or II, who did not have trauma or were initially admitted to ICU, aged 18-65, without preexisting cardiac, renal, or pulmonary disease. Patients were divided into three groups: those acutely positive for methamphetamine within 48 hours of surgery (n = 137), those positive for methamphetamine between 48 hours and 7 days of surgery (n = 69), and randomly selected controls who were negative for methamphetamine within 7 days of surgery (n = 159). Measurements. Intraoperative hemodynamic instability was defined as either a drop of more than 40% in MAP for greater than 5 minutes or requirement for significant amount of vasopressors. Main Results. Among the patients who were acutely positive for methamphetamine within 24 hours, 31.4% met the criteria for hemodynamic instability within the first hour of general anesthesia, compared to 26.1% of the subacutely positive patients and 6.3% of controls (p < 0.0001). This was despite lower doses of anesthetic medications in the acutely and subacutely positive groups.Entities:
Year: 2022 PMID: 35222639 PMCID: PMC8872671 DOI: 10.1155/2022/7542311
Source DB: PubMed Journal: Anesthesiol Res Pract ISSN: 1687-6962
Figure 1Inclusions and exclusions. CHF: congestive heart failure. COPD: chronic obstructive pulmonary disease. ESRD: end-stage renal disease. HTN: hypertension. LSD: lysergic acid diethylamide. MICU/SICU: medical intensive care unit/surgical intensive care unit. TIVA: total intravenous anesthesia. UDS: urine drug screen.
Demographic summary.
| No meth ( | Subacute positive ( | Acute positive ( |
| |
|---|---|---|---|---|
| Sex | ||||
| Female | 45 (28.3%) | 12 (17.4%) | 24 (17.5%) | 0.048 |
| Male | 114 (71.7%) | 57 (82.6%) | 113 (82.5%) | |
| Age | 33.7 ± 11.4 | 36.1 ± 10.4 | 38.3 ± 11.5 | 0.002 |
| Age group | ||||
| Age 16 to 30 | 74 (46.5%) | 22 (31.9%) | 41 (29.9%) | 0.004 |
| Age 31 to 40 | 43 (27%) | 24 (34.8%) | 37 (27%) | |
| Age 41 to 50 | 27 (17%) | 16 (23.2%) | 38 (27.7%) | |
| Age 51 to 60 | 15 (9.4%) | 7 (10.1%) | 14 (10.2%) | |
| Age >61 | 0 (0%) | 0 (0%) | 7 (5.1%) | |
| Modified ASA | ||||
| 1 | 27 (17%) | 6 (8.7%) | 6 (4.4%) | 0.002 |
| 2 | 132 (83%) | 63 (91.3%) | 131 (95.6%) | |
| Surgery performed | ||||
| GI | 0 (0%) | 1 (1.5%) | 1 (0.7%) | Not applicable |
| GYN | 0 (0%) | 0 (0%) | 1 (0.7%) | |
| General surgery | 26 (17.2%) | 10 (14.7%) | 14 (10.4%) | |
| OMFS | 16 (10.6%) | 7 (10.3%) | 3 (2.2%) | |
| Ophtho | 0 (0%) | 0 (0%) | 1 (0.7%) | |
| Ortho | 107 (70.9%) | 50 (73.5%) | 113 (83.7%) | |
| Podiatry | 1 (0.7%) | 0 (0%) | 0 (0%) | |
| Urology | 1 (0.7%) | 0 (0%) | 2 (1.5%) | |
| Inhaled agent | ||||
| Isoflurane | 0 (0%) | 1 (1.5%) | 0 (0%) | Not applicable |
| Sevoflurane | 159 (100%) | 68 (98.6%) | 136 (100%) | Not applicable |
| N2O status | ||||
| Did not receive N2O | 86 (54.1%) | 38 (55.1%) | 84 (61.3%) | 0.429 |
| Received N2O | 73 (45.9%) | 31 (44.9%) | 53 (38.7%) | |
| Phenylephrine dose mcg | 216 ± 200 | 527 ± 614 | 568 ± 653 | 0.003 |
| Ephedrine dose mg | 8.6 ± 4.1 | 14.3 ± 10.1 | 29.2 ± 28.8 | 0.016 |
| Epinephrine dose mcg† | Not applicable | Not applicable | 102 ± 139 | Not applicable |
| Vasopressin dose units† | Not applicable | Not applicable | 5 ± 1 | Not applicable |
| Average sevoflurane/isoflurane concentration % | 2 ± 0.5 | 1.9 ± 0.8 | 1.9 ± 0.6 | 0.175 |
| Average N2O concentration % (patients who received N2O) | 51.3 ± 3.3 | 50 ± 0 | 50.9 ± 5.1 | 0.447 |
| Propofol dose mg/kg | 2.5 ± 0.7 | 2.7 ± 0.9 | 2.3 ± 0.6 | 0.001 |
| Fentanyl dose mcg/kg | 185 ± 65 | 182 ± 74 | 177 ± 63 | 0.549 |
| Dilaudid dose mg/kg (all patients) | 0.0374 ± 0.0056 | 0.00171 ± 0.105 | 0.00395 ± 0.0069 | 0.093 |
| Dilaudid dose mg/kg (patents who received dilaudid) | 0.0091 ± 0.0054 | 0.0422 ± 0.1643 | 0.0120 ± 0.0070 | 0.119 |
| Morphine dose mg/kg | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0.135 |
∗Zero patients in control and only two patients in each of the investigation groups receive morphine. †Zero patients in control and subacute groups received vasopressin or epinephrine.
Comparison of clinical outcomes among the three study groups.
| No meth ( | Subacute positive ( | Acute positive ( |
| |
|---|---|---|---|---|
| Blood pressure at 0 min (SBP/DBP (MAP) mean ± SD) | 122.7 ± 12.7/68.7 ± 10.3(75.1 ± 12.6) | 120.9 ± 15.7/69.8 ± 11.8(77.1 ± 12.8) | 128.2 ± 18.6/74 ± 12.7(83.6 ± 14.9) | 0.0014/0.0004(<0.0001) |
| Heart rate at 0 min (mean ± SD) | 85.9 ± 9.4 | 86 ± 12 | 91.2 ± 13.4 | 0.0002 |
| Blood pressure between 5 and 60 min (SBP/DBP (MAP) mean ± SD) | 109.9 ± 9.7/62.1 ± 9.8(77.2 ± 8.6) | 108.6 ± 11.5/62.6 ± 9.2(77.2 ± 8.9) | 108.2 ± 10.6/62.8 ± 8.9(77.2 ± 8.6) | 0.3766/0.7972(0.9968) |
| Mean HR between 5 and 60 min (mean ± SD) | 75.1 ± 12 | 78.3 ± 12.1 | 83.8 ± 15 | <.0001 |
| Hemodynamic instability, | 10 (6.3) | 18 (26.1) | 43 (31.4) | <.0001 |
| Hemodynamic instability by MAP criteria only, n | 2 | 0 | 6 | |
| Hemodynamic instability by medication criteria only, n | 8 | 17 | 28 | |
| Hemodynamic instability by both criteria, n | 0 | 1 | 9 |
DBP: diastolic blood pressure. HR: heart rate. MAP: mean arterial blood pressure. SBP: systolic blood pressure. SD: standard deviation.
Medication usage by the three study groups.
| No meth ( | Subacute UDS ( | Acutely UDS positive ( | |||||
|---|---|---|---|---|---|---|---|
|
| Mean ± SD |
| Mean ± SD |
| Mean ± SD | ||
| Amount of phenylephrine (all patients) | 45 | 215.6 ± 199.9 | 38 | 527 ± 613.6 | 75 | 567.3 ± 652.5 | 0.0028 |
| Amount of phenylephrine (patients who received phenylephrine) | 8 | 550 ± 277.7 | 17 | 951.5 ± 718.5 | 39 | 905.1 ± 761.4 | |
| Amount of ephedrine (all patients) | 14 | 8.6 ± 4.1 | 11 | 14.3 ± 10.1 | 12 | 29.2 ± 28.8 | 0.0162 |
| Amount of ephedrine (patients who received ephedrine) | 3 | See footnote | 7 | 17.9 ± 11.1 | 9 | 35.6 ± 30.9 | |
| Amount of epinephrine (all patients) | 0 | Not applicable | 0 | Not applicable | 2 | See footnote | Not applicable |
| Amount of epinephrine (patients who received epinephrine) | 0 | Not applicable | 0 | Not applicable | 2 | See footnote | |
| Amount of vasopressin (all patients) | 0 | Not applicable | 0 | Not applicable | 3 | See footnote | Not applicable |
| Amount of vasopressin (patients who received vasopressin) | 0 | Not applicable | 1 | Not applicable | 3 | See footnote | |
∗Descriptive statistics were not reported for subgroups with 3 or fewer observations.